Research summary, original research, 2017

Dose reduction for fluoroscopically guided injections: phantom simulation and patient procedures

Chang CY, Simeone FJ, DeLorenzo MC, Palmer WE, Bredella MA, Huang AJ. Skeletal radiology. 2017

Read the original paper

In plain language

In 1,094 fluoroscopy-guided joint injections and a phantom, simple dose-minimization techniques cut fluoroscopy time and dose-area product by about two-thirds. Operator dose was not measured, but lower patient dose generally means less scatter for the fluoroscopy team.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients, Phantom or simulation (no people), Other physicians
Size
n = 1,094 injections
Summary based on
the abstract

What it found

  • In patient injections, applying the dose minimization technique lowered fluoroscopy time, dose and dose-area product (DAP) for all three operators.

    Key figures: FT 0.7 to 0.2 min; dose 5.6 to 1.9 mGy; DAP 56.9 to 19.1 μGy·m2

  • In phantom simulation of hip joint injections, DMT cut total DAP about tenfold and lowered entrance dose.

    Key figures: DAP 191.7 vs 18.7 μGy·m2; entrance dose 10.2 vs 3.6 mGy

  • Reductions remained significant for the two most common injections, glenohumeral and hip.

    Key figures: P < 0.05

  • DMT reduced effective and organ doses in simulated men and women.

Limits to keep in mind

Single-suite before-after comparison with three operators and phantom simulation; staff dose was not measured directly, so the benefit to the operator is inferred from patient dose metrics. The abstract does not describe the DMT components and misstates the significance threshold as P > 0.05.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.